2019
BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer
Lu L, Huang H, Zhou J, Ma W, Mackay S, Wang Z. BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. BMC Cancer 2019, 19: 387. PMID: 31023256, PMCID: PMC6482542, DOI: 10.1186/s12885-019-5595-3.Peer-Reviewed Original ResearchConceptsT cell activation statusCell activation statusPatient survivalT cell activationBreast cancerActivation statusCCND1 levelsCell activationT cell activation scoreCCND1 expressionKaplan-Meier survival curvesAdjusted hazard ratioCCND1 expression levelsBreast cancer patient survivalImmune checkpoint blockadeBetter overall survivalBreast cancer patientsCox regression modelCancer patient survivalT cell recognitionBRCA1 levelsBRCA1 mRNA expressionCheckpoint blockadeHazard ratioOverall survival
2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31: 4559-4566. PMID: 22139083, PMCID: PMC3342446, DOI: 10.1038/onc.2011.539.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCarboplatinCell Line, TumorCell SurvivalDrug Resistance, NeoplasmFemaleGenotypeHumansKaplan-Meier EstimateMiddle AgedMultivariate AnalysisMutationNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPolymorphism, Single NucleotidePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRNA InterferenceTreatment OutcomeConceptsEpithelial ovarian cancerEOC patientsKRAS-variantOvarian cancerPoor outcomeCancer riskTumor biologyPlatinum resistanceComplete clinical dataBiomarkers of outcomeDirect targetingEOC cell growthKnown BRCA mutationsFuture treatment approachesSubset of tumorsPlatinum chemotherapy resistanceCell linesNeoadjuvant chemotherapyBRCA mutationsClinical dataTreatment approachesChemotherapy resistanceKRAS oncogeneMultivariate analysisPatients
2007
Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.
Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Yu H. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 2007, 16: 395-403. PMID: 17913048, DOI: 10.3727/000000006783980892.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsATP Binding Cassette Transporter, Subfamily B, Member 1Biomarkers, TumorBRCA1 ProteinCyclin-Dependent Kinase Inhibitor p16Disease ProgressionDrug Resistance, MultipleEstrogen Receptor alphaFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsPrognosisRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, NeoplasmSurvival AnalysisTreatment OutcomeConceptsMDR1 expressionClinicopathological parametersDisease progressionOvarian cancer cohortEpithelial ovarian cancerOvarian cancer prognosisOvarian cancer treatmentOvarian cancer progressionExpression of MDR1Ovarian tumor samplesOverall survivalPatient ageOvarian tumorsIGF-IIQuantitative real-time PCROvarian cancerCancer cohortReal-time PCRIndependent markerCancer prognosisDrug resistanceTumor samplesCancer treatmentCancer progressionERalpha